Treatment of fungal infections in neutropenic children

T Lehrnbecher1, A H Groll, S J Chanock

  • 1Immunocompromised Host Section, National Cancer Institutes of Health, Bethesda, MD 20892, USA.

Insights

Fungal infections are a major risk for children undergoing cancer treatment and marrow transplants. This review covers new antifungal therapies for these immunocompromised children.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Hematology

Background:

  • Fungal infections are a significant complication in pediatric patients undergoing antineoplastic therapy and marrow transplantation.
  • High morbidity and mortality rates are associated with these infections.
  • Increasing incidence and spectrum of fungal infections are observed due to intensive treatments and improved management of other infections.

Purpose of the Study:

  • To review the therapeutic options for treating fungal infections in immunocompromised children.
  • To highlight recent advances in antifungal therapies.

Main Methods:

  • Literature review of antifungal therapies for immunocompromised children.
  • Discussion of risk factors, including prolonged neutropenia.
  • Overview of current and emerging antifungal agents.

Main Results:

  • Prolonged neutropenia is the primary risk factor for fungal infections.
  • Limited therapeutic options previously existed.
  • Advances include less toxic amphotericin B formulations, new azoles, and novel antifungal compounds.

Conclusions:

  • Effective management of fungal infections in immunocompromised children requires awareness of risk factors and available therapeutic options.
  • Recent advances have expanded the armamentarium for treating these serious infections.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...